Abstract：
UNASSIGNED: Psoriasis significantly impacts patients\' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.
UNASSIGNED: This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.
UNASSIGNED: Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.
UNASSIGNED: The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.
UNASSIGNED: Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.
UNASSIGNED: This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.
UNASSIGNED: Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.
UNASSIGNED: The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.
UNASSIGNED: Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.
摘要：
■银屑病显著影响患者的生活质量(QoL)。不满意和不坚持是与局部治疗相关的主要障碍。设计了一种基于多微泡分散体（PAD）技术的乳膏，该乳膏包含固定剂量的卡泊三醇（CAL）和二丙酸倍他米松（BDP），用于患者友好的牛皮癣管理。CAL/BDPPAD霜显示出功效，便利性，和临床试验中的安全性/耐受性。
■这项研究评估了现实世界的使用，感知，满意,和CAL/BDPPAD-乳膏在斑块状银屑病患者中的依从性。
在2023年9月至11月之间，通过Wefight网络招募了来自西班牙和德国的使用或使用CAL/BDPPAD-乳膏>2周的牛皮癣患者，以完成30个问题的在线调查。将匿名结果合并用于描述性统计分析。
■该调查由129名患者完成（平均年龄：43岁；66％女性；平均牛皮癣持续时间：12年）。大多数患者（93％）对CAL/BDPPAD乳膏感到满意。66％的人报告了高依从性（视觉模拟评分80-100），91％的人首选CAL/BDPPAD-乳膏，以其先前的局部用药。患者强调其应用的易用性/便利性，耐受性,和缺乏瘙痒/燃烧。
■在真实世界环境中接受CAL/BDPPAD霜治疗的银屑病患者表现出很高的满意度，良好的坚持,以及对产品的积极看法，表明临床试验中观察到的有利结果转化为真正的临床实践。
■这项研究评估了现实世界的使用，感知，满意,和CAL/BDPPAD-乳膏在斑块状银屑病患者中的依从性。
在2023年9月至11月之间，通过Wefight网络招募了来自西班牙和德国的使用或使用CAL/BDPPAD-乳膏>2周的牛皮癣患者，以完成30个问题的在线调查。将匿名结果合并用于描述性统计分析。
■该调查由129名患者完成（平均年龄：43岁；66％女性；平均牛皮癣持续时间：12年）。大多数患者（93％）对CAL/BDPPAD乳膏感到满意。66％的人报告了高依从性（视觉模拟评分80-100），91％的人首选CAL/BDPPAD-乳膏，以其先前的局部用药。患者强调其应用的易用性/便利性，耐受性,和缺乏瘙痒/燃烧。
■在真实世界环境中接受CAL/BDPPAD霜治疗的银屑病患者表现出很高的满意度，良好的坚持,以及对产品的积极看法，表明临床试验中观察到的有利结果转化为真正的临床实践。
